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We assessed how opioid agonist treatment (OAT) for opioid use disorder (OUD), specifically 
methadone and buprenorphine, including buprenorphine-naloxone, is delivered in routine 
clinical practice, with a focus on factors that affect access to and delivery of these services. 
The aims of this review were to summarize eligibility criteria for entry to OAT, doses in 
routine clinical practice, access to and eligibility for unsupervised dosing, and urine drug 




We completed searches of PubMed, Embase, and grey literature databases for cross-
sectional or observational cohort studies of OAT using either methadone or buprenorphine. 




We found 140 reports from 41 countries that contained data for at least one of the relevant 
indicators. A diagnosis of opioid dependence or opioid use disorder was the most common 
eligibility requirement for OAT (13 or 17 countries). Reported mean or median doses for 
methadone ranged from 16 to 131 mg while range for buprenorphine was 2.5 – 19 mg.   
Access to unsupervised dosing under some conditions was reported in 18 of 27 countries.  
Frequency of regular urine drug screenings (UDS) ranged from several times a week to eight 




Opioid agonist treatment practices, including doses prescribed, vary greatly both within and 
across countries. Of particular concern is the persistence of lower dose prescribing practices, 
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Opioid use disorder (OUD) is an important public health issue, affecting an estimated 40.5 
million people globally in 2017.1 OUD is characterized by physical dependence and/or 
continued self-administration of opioids (illicit or pharmaceutical) with loss of control over 
use, including use despite adverse consequences, and craving.2  Opioid agonist treatment 
(OAT; e.g. methadone or buprenorphine prescribed over an extended period of time) is 
effective in managing OUD, improving physical, behavioral, and psychological health of 
individuals with OUD,3, 4 reducing the risk of infectious disease transmission due to unsafe 
injection practices,5, 6 and reducing risk of mortality.7 OAT prevents withdrawal, provides 
opioid receptor blockade, and helps reduce or eliminate cravings to use opioids.  
 
The number of countries in which OAT is available is rising. A 2017 systematic review of HIV 
prevention interventions for people who inject drugs (PWID) found that OAT was available in 
86 countries, including methadone in 81 countries and buprenorphine in 56,8 compared to 
what was available in 2010 – methadone in 61 countries and buprenorphine in 41 countries.9 
Information regarding the implementation and uptake of OAT has become more readily 
available since the first systematic review of global OAT coverage was published in 2010;9 
however, to the best of our knowledge, there are no published systematic reviews that focus 
on the characteristics of delivery of OAT worldwide.  
 
The World Health Organization (WHO) published guidelines in 2009 for the delivery of 
psychologically assisted pharmacological treatment of people with OUD based on published 
literature and the expertise of content experts.10 These guidelines included dosing 
recommendations for both methadone and buprenorphine, outlining recommended initial and 
continued dose ranges. The guidelines for methadone recommend an initial dose of less 
than 20 mg/day and an ongoing treatment dose of 60 -120 mg/day, and the guidelines for 
buprenorphine recommend an initial dose from 2 – 8 mg/day and an ongoing treatment dose 
of at least 8 mg/day.  
 
The WHO guidelines also recommended that methadone and buprenorphine consumption 
be supervised in the early stages of treatment to maximize treatment adherence and 
minimize risks such as diversion to other persons and non-prescribed use by injection. There 
is less guidance regarding ongoing supervision throughout treatment. Supervised dosing 
throughout treatment aims to maximize treatment adherence and minimize diversion of 
medications to the unregulated market. However, daily supervised dosing for all patients 
receiving OAT is resource-intensive and can be onerous for patients.11 In some settings, 
unsupervised dosing (i.e., “take-away” or “take-home” doses) may be provided at the 
discretion of the prescribing doctor to patients who demonstrate “stability”, but there has 
been little research to inform this clinical decision.12 Balancing patient safety with the need 
for more flexible treatment with less supervision is a complex task with critical implications 
for patient and community safety. 
 
The WHO guidelines omit any specific recommendations on urine drug screening (UDS) for 
the purposes of treatment monitoring, although an initial screen for opioids is recommended 
as part of assessment and treatment induction. Health care providers may use UDS to 
assess how a patient’s treatment is progressing. For example, a positive UDS for extra-
medically consumed opioids may indicate a need to review a patient’s dose or adjust the 




few published papers that have evaluated the effectiveness of mandatory UDS on patient 
health outcomes did not find clear benefits of this practice on patient outcomes.13  
 
In this review we assess how OAT for OUD (specifically methadone and buprenorphine, 
including buprenorphine-naloxone) is delivered in routine clinical practice, with a focus on 
factors that affect access to and delivery of these services. The aims of this review are to 
document and summarize at a country level: 
1.       Eligibility criteria for entry to OAT  
2.       Doses of methadone and buprenorphine as prescribed in routine clinical practice 
3.       Access to unsupervised dosing and eligibility to receive unsupervised doses 
4.       Urine drug screening practices in OAT programs, including indications for UDS and 








There has been considerable debate in recent years over appropriate terminology to 
describe the use of methadone and buprenorphine to treat OUD.14-16 Prior to the introduction 
of buprenorphine, ‘methadone maintenance treatment’ was a widely used term, which 
remains in use in some parts of the world (e.g. China). ‘Opioid substitution treatment’ is used 
by the WHO and other UN agencies to refer to treatment with methadone or 
buprenorphine.14-17 ‘Opioid agonist treatment’ is increasingly used with the argument that it is 
more precise and less open to misinterpretation than its predecessors.15 We therefore use 
the terminology ‘opioid agonist treatment’ and the abbreviation OAT in this review but 
included all previous descriptor terms in conducting our literature search. 
  
Studies of OAT using either methadone or buprenorphine for OUD were included (with any 
of the above terminologies). Where buprenorphine is referred to, this includes 
buprenorphine-naloxone coformulation. This review does not include other opioids used for 
treatment of OUD in relatively few countries (e.g. slow-release oral morphine; tincture of 
opium; injectable diamorphine; injectable hydromorphone), recently approved depot and 
implant forms of buprenorphine, or opioid antagonists (e.g. naltrexone).   
 
Search strategy and study selection  
This review included searches of peer-reviewed and grey literatures. This review is reported 
in line with the PRISMA guidelines for reporting of systematic reviews. We searched 
PubMed and Embase in July 2018 to identify relevant peer-reviewed literature. As many of 
the indicators of interest are not typically used as study outcomes, but may be reported 
incidentally in a paper’s background or methods, our search strategy had to balance 
comprehensiveness (identifying as many potentially relevant studies as possible) with 
capacity to screen the resulting list of studies. Search terms are provided in the 
Supplementary Materials. Searches were limited to papers published from 2010 onwards to 
ensure that data reflected recent clinical practice.  
 
Eligible reports were cross-sectional or observational cohort studies of people receiving 
OAT, or papers describing an OAT program, presenting information relevant to at least one 
of the selected indicators. Where longitudinal studies were included, baseline data were 
extracted. Reports of clinical trials were excluded as these may not reflect standard 
treatment practices (e.g. strict eligibility criteria; pre-specified dosing protocols; frequent UDS 
to measure trial outcomes). Studies were excluded from dose analyses if the study design 
focused on a subset of patients receiving OAT (e.g. a specific race/ethnic group) as the 
reported data may not reflect data for all patients in that program or area; however, if such 
reports included other information relevant to the indicators of interest (e.g. unsupervised 
dosing policies), the report was included for that indicator. We did not include assessments 
of clinical guidelines for OAT, as these may not be indicative of actual clinical practice. 
 
Initial search results were screened on the basis of title and abstract by a team including SL, 
HJ, and four research assistants. The full-text of studies shortlisted on this basis were 
double-screened independently by the same team, with conflicts resolved through 





In addition to peer-reviewed literature, a database of grey literature on HIV prevention 
interventions for PWID, including OAT, assembled for a previous systematic review,8 was 
searched for additional reports containing relevant data. This database was screened by one 
research assistant, then SL identified relevant reports from the shortlisted studies. Five 
further reports were identified by co-authors at the data extraction stage and added to the 
shortlisted studies.  
 
 
We identified during data extraction that many papers reported data from substantially earlier 
time periods, potentially limiting the relevance of the information to current clinical practice. 
We therefore elected to include only data relating to clinical practices from 2010 onwards 
(i.e. data collection for the study occurred during the past decade). Where data were 
collected over a period of several years, we included the data if the time period 
encompassed 2010. Where year of data collection was not reported, we assumed data were 
collected two years prior to the publication year.  
 
Data extraction 
Data were extracted into a spreadsheet by the search team. All data points were checked 
against the original report for accuracy by the senior author. Information extracted on 
eligibility criteria to commence OAT included any reported requirement for treatment entry, 
such as patient age, diagnosis, assessments to be completed, or requirements to be non-
responsive to other treatment modalities prior to OAT. For methadone and buprenorphine 
doses, we extracted mean or median doses and their associated measures of dispersion. 
Where reports provided the proportion of patients receiving doses above 60mg of 
methadone or 8mg of buprenorphine, this information was also extracted. 
 
We defined ‘unsupervised dosing’ as doses of methadone or buprenorphine that patients 
were permitted to take away from and consume outside of a healthcare facility or dispensing 
location. Information extracted for this indicator included whether unsupervised dosing was 
permitted, and eligibility criteria for unsupervised dosing. For UDS indicators, we extracted 
information on the frequency of UDS and implications for patients of a positive (or negative) 
UDS.  
 
Risk of bias 
Risk of bias assessments give an indication of how study design and conduct may have 
influenced an outcome. Given the nature of this review in searching for data that are 
frequently reported incidentally rather than as part of study design or outcomes, we did not 
complete a risk of bias assessment. 
 
Data analysis 
We had planned to undertake a meta-analysis of mean methadone and buprenorphine 
doses reported in the included studies. However, much of the extracted dose data was 
missing standard deviations, or reported medians rather than means. Rather, dose data are 
reported as minimum and maximum mean and/or median doses identified both within and 
across all reports identified for that country. The minimum and maximum proportions of 






For the remaining indicators (treatment eligibility, access to unsupervised dosing, and use of 
UDS), data for each indicator were first grouped by country. For each indicator, data for each 
country were qualitatively synthesized to produce a summary for that country. For some 
indicators (e.g. access to unsupervised dosing), this was relatively straightforward as for the 
most part only yes/no information was available. For others (e.g. use of UDS), different 
studies provided different information, reflecting varying practices between treatment sites. 
In these instances, the resulting summary captured the range of practices reported. Data 
management was conducted in Excel and meta-analysis synthesis was conducted using a 
random effects model using STATA. This analysis was not pre-registered on a publicly 








The peer-reviewed literature search returned 7,415 results for screening, and the grey 
literature database provided 137 reports for screening. After screening and exclusions, 140 
reports from 41 countries contained data for at least one of the relevant indicators (Figure 1).  
  
Eligibility for OAT  
We identified 32 reports from 17 countries that described eligibility criteria and restrictions to 
entry for OAT. Findings are summarized in Table 1 and complete data are provided in 
Supplementary Table 1. As expected, a diagnosis of opioid dependence or opioid use 
disorder (DSM-IV or ICD) was required to be eligible for OAT in most countries (13/17 = 
76%). Assessment by specialists (e.g. psychiatrists) or confirmation of OUD diagnosis by 
multiple physicians or multidisciplinary teams were required in some instances. A minimum 
age requirement (usually 18) was mentioned for 6 . Other treatment entry criteria included 
prior attempts at non-pharmacological treatment for OUD (Armenia and Kyrgyzstan),18, 19  an 
“unsuccessful” detoxification attempt ( Finland20 and Iran) or evidence of recent use by an  
opioid positive urine test (Israel, Macao, Tanzania). Requirements for people to have 
completed detention in a compulsory detoxification centre prior to OAT entry were removed 
in China in 2006.21 Requirements that people entering OAT have their details reported to law 
enforcement registries were identified in Armenia, Azerbaijan and China.   
Methadone and buprenorphine doses prescribed in routine clinical practice 
There were 101 reports from 34 countries providing data on prescribed doses of methadone 
or buprenorphine. Findings are summarised in Tables 2 and 3, with countries ordered by 
doses prescribed, and complete data are provided in Supplementary Tables 2 and 3. 
 
The first nine countries listed report prescribing high mean doses of 73-131 mg and an 
additional country (Malaysia) reports a high percentage maintained on doses >80 mg  The 
next group of 13 countries report a wide range of doses that encompass 48-119 mg and 
includes Ireland that reports a substantial percentage on >=60mg.  The final group of 10 
countries report lower doses with a range that encompasses mean doses as low as 16 mg 
(Nepal) and as high as 69 mg (China).  The percentage of patients receiving doses >=60mg 
generally corresponds to mean dose ranges where this data is available. 
Considerably fewer data were identified for buprenorphine dose levels. Table 3 shows data 
for 15 countries where data were available. The first 6 countries listed report high mean 
buprenorphine dose ranges that encompass 10-19 mg. the next group of 7 countries report 
mean doses from 5.8 - 9.2 mg.  Only Nepal reports using very low doses.   
Availability of unsupervised dosing 
 
Information on availability of unsupervised dosing was extracted from 52 reports from 27 
countries (results summarized in Table 4 and complete data provided in Supplementary 
Table 4 Unsupervised dosing was permitted in 18 of 27 countries (67%) at least under some 
conditions. Typically this practice was implemented at the discretion of the prescribing 
physician for patients considered suitable. Some reports noted objective indicators that were 
used to determine suitability for unsupervised dosing, including compliance with program 
rules or negative UDS.   
 





We identified 51 reports from 17 countries that provided information on UDS practices in 
OAT settings (results summarized in Table 5; complete data are provided in Supplementary 
Table 5). The information presented was typically limited to frequency of screening with 
minimal details regarding rationale for or events that may trigger UDS.  
 
The frequency of UDS varied from several times a week (e.g. some reports from Israel;18, 19 
one report from the US20) to once a month (e.g. patients receiving buprenorphine after 
stabilisation in some US settings21), while others stated that UDS was undertaken as 
clinically indicated. Several reports indicated that the collection of urine samples was 
supervised; for example, via one-way mirror.22 In Hong Kong, UDS was undertaken for 
program monitoring purposes only, and was entirely voluntary.23 Some reports from the 
United States noted that the frequency of UDS was dictated by the patient’s insurance 
company24 or parole terms,25 rather than clinical factors. 
 
Reported implications of a positive UDS for the patient included decreased access to 
unsupervised dosing and increased clinical visits. Positive UDS results could also lead to 
removal from treatment, although most reports noted that this occurred only if clinical 
interventions (e.g. increased physician visits or counselling) in response to the positive result 










In this global systematic review, we found wide variation between, and sometimes within, 
countries in the way OAT is delivered. Our findings suggest that there are considerable 
opportunities to improve clinical practice in the delivery of OAT.  
 
Opioid use disorder/opioid dependence was the main treatment eligibility criterion in most 
settings  which seems appropriate. However, restrictive entry criteria for OAT were 
sometimes reported, including prior attempts at non-pharmacological treatment. Additionally, 
several countries require that the details of patients who receive OAT are provided to law 
enforcement agencies. The reasoning behind such registration was not made explicit in the 
identified reports but does not appear to have any clinical purpose and likely acts as a 
barrier to treatment entry. Satisfactorily addressing the concerns of communities and law 
enforcement is a key challenge in scaling up OAT in many settings and may require changes 
in the legal and cultural landscape in such countries. Strict laws and aggressive policing 
have also made it difficult for public health agencies to implement and expand evidence-
based interventions to treat OUD.26-28 There are published accounts of law enforcement 
targeting PWID at treatment facilities,29 intimidating health care providers,29, 30 and 
confiscating sterile syringes.31 These practices actively deter PWID from seeking treatment 
and prevent providers from serving their patients. Encouragingly, a study in Kyrgyzstan that 
examined the effects of integrating police training with public health education has shown 
promise and may serve as a feasible model for law enforcement agencies in countries with 
similar epidemics.32  
 
Importantly, our data indicate that many people prescribed OAT are prescribed doses below 
those that are considered optimal for clinical benefit. A 2003 systematic review that 
evaluated the efficacy of different doses of methadone found that doses ranging from 60 - 
100 mg/day were more effective in retaining patients in treatment and reducing substance 
use during treatment compared to lower doses (1-39 mg/day).33 A review of the literature 
regarding buprenorphine dosing noted that doses above 16 mg resulted in greater clinical 
benefit than doses between 8-16 mg.34 Only 2 of 12 countries had doses of 16 mg or high in 
our data (Table 3). Additionally, there is some evidence that higher doses of OAT may 
reduce non-opioid use among patients receiving OAT. Two RCTs found that patients who 
received higher doses of OAT had a greater probability of abstaining from cocaine compared 
to those who received lower doses.35, 36 For several countries, multiple data sources 
confirmed low dosing to be a concern. Our results suggest that a large proportion of patients 
receiving OAT are not prescribed doses high enough to promote cessation of extra-medical 
opioid use, which may undermine the clinical and public health benefits of OAT. Our finding 
that many OAT patients are prescribed doses below those that are considered minimal for 
producing clinical benefit has also been reported in other studies.37, 38 
 
Unsupervised dosing was not permitted at all in several settings. Lack of access to 
unsupervised dosing has been identified as an important barrier to OAT entry and retention, 
as daily attendance for dosing can be onerous, time-consuming, and expensive.39, 40 
Requiring daily supervised dosing is also resource-intensive for treatment providers, 
potentially limiting treatment capacity.41 That said, in countries where unsupervised dosing is 
widespread, the introduction of higher levels of supervised methadone dosing was followed 




supervision can be implemented safely, particularly in relation to buprenorphine prescribing, 
and are already in use in some settings.41, 43, 44 Research to identify patients most suited to 
lower levels of supervision, and those in need of higher levels of supervision, is still needed.  
 
Where unsupervised dosing is available, the proportion of patients receiving any 
unsupervised doses was rarely reported, so we were unable to assess the extent to which 
policies permitting unsupervised dosing are put into practice. In determining access to 
unsupervised dosing, mention was often made of physician discretion in determining 
‘stability’ or other indicators of suitability; however, given there are no universally agreed 
upon criteria for stability, there is likely variation and subjectivity (allowing for bias) in defining 
and measuring ‘stability’, and in practice there may be little relationship between indicators of 
treatment adherence and access to unsupervised dosing.12 A recent study reported no 
association between adherence to the treatment regimen and the number of unsupervised 
doses prescribed, and suggested that system-level factors (e.g., location, what type of OAT 
is available, if the prescriber worked in a public or private practice), and not patient 
behaviors, are more likely to dictate who would be eligible for take-home doses.12 
Paradoxically, one study in London found that patients receiving OAT who were less 
adherent to their treatment regimen were more likely to be prescribed take-home doses 
compared to those who fully adhered.45 Research comparing the effects of supervised to 
unsupervised dosing is lacking,46 though there have been a small number of randomized 
controlled trials comparing the effects of these two strategies. Two trials, one conducted in 
Australia47 and another Scotland,48 reported no differences in treatment retention nor 
medication adherence between patients who were and were not prescribed take-home 
doses. However, another trial conducted in Italy found that patients receiving OAT who were 
assigned supervised daily consumption had a higher retention rate than those who were 
assigned take-home doses.49 A qualitative study found that patients recognized the value of 
supervised dosing at the beginning of treatment as it may help establish a daily routine and 
were accepting of supervised dosing with the potential of modification at a later time.42 
However, there is also concern that supervised dosing may jeopardize patient privacy and 
may lead to increased stigma.50, 51  
 
 
Frequent urine drug screening was mandated in many of the settings reviewed here. In 
some reports from the United States, it was noted that insurance companies or parole 
officers determined the frequency of UDS rather than clinicians. A recent systematic review 
identified only one evaluation of the impact of UDS on OAT outcomes, finding that providing 
take-home doses, contingent on negative UDS results, increased treatment retention.52 This 
study did not examine the impact of UDS on treatment retention or other outcomes directly. 
The review concluded that there is very little evidence on the effectiveness of UDS in OAT 
on clinical or public health outcomes.52 Given that UDS has cost implications, is potentially 
embarrassing and invasive for patients, may perpetuate substance-use stigma, and is 
currently implemented in a highly variable way with little evidence-based guidance, there is a 
clear need for methodologically rigorous research that establishes whether UDS improves 
OUD treatment outcomes, and the frequency of testing and other aspects (e.g., direct 
observation) of how UDS is implemented that are required to achieve this.  
 
This study has several imitations. Our review only included clinical practices that were 




clinical practices of facilities that have contributed to the literature which may not reflect 
overall practices within a country. Further, the number of clinics represented in the literature 
in relation to the total number operating in each country is unknown. We are unable to 
comment on practices in countries that lacked reports; we identified reports relating to 41 
countries, but there are at least 86 countries where OAT is implemented to some extent.8 
We used a comprehensive search strategy, but it is possible that papers relevant to our 
study’s objectives may have been overlooked or mistakenly excluded.  
 
We restricted the data included in this analysis to those reported in peer-reviewed 
publications and grey literature. We chose not to review clinical guidelines or treatment 
policies as these may not be translated into clinical practices, since our focus was on 
reporting what happens in routine clinical care. National guidelines may provide broader, and 
possibly, more comprehensive protocols for OAT entry and clinical care. Additional research 
examining national guidelines may be warranted. Similarly, research examining OAT legal 
and policy environments globally may shed light on how practices may vary between 
countries, and opportunities to improve care. 
 
Clearly there is a need to collate and pool observational data from OAT across countries to 
improve the evidence base and motivate cross-country comparisons and studies on OAT 
delivery and drug related harms. We did not evaluate all aspects of OAT care, such as 
whether patients have access to counselling or other psychosocial support, whether 
treatment is accessed in specialty or primary care settings, or availability of OAT dispensing 
in community pharmacy settings.53 We cannot assume that the studies that we identified are 
reflective of all clinical practice in a given country and have noted where variation was 
observed between studies from one country.  
 
Despite these limitations, our study provides a comprehensive overview of OAT in clinical 
practice. The data provided by peer-reviewed articles that describe OAT in practice reported 
that doses prescribed to patients varied greatly within countries and globally, and that a large 
proportion of patients may be prescribed doses below those proven to yield significant 
clinical benefits. Further research is necessary to understand why there is such variability in 
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